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The boron-oxygen core of borinate esters is
responsible for the store-operated calcium entry
potentiation ability
Olivier Dellis1,2*, Pierre Mercier1, Christine Chomienne1
Abstract
Background: Store-Operated Calcium Entry (SOCE) is the major Ca2+ ion entry pathway in lymphocytes and is
responsible of a severe combined immunodeficiency (SCID) when deficient. It has recently been observed or
highlighted in other cell types such as myoblasts and neurons, suggesting a wider physiological role of this
pathway. Whereas Orai1 protein is considered to be the channel allowing the SOCE in T cells, it is hypothesized
that other proteins like TRPC could associate with Orai1 to form SOCE with different pharmacology and kinetics in
other cell types. Unraveling SOCE cell functions requires specific effectors to be identified, just as dihydropyridines
were crucial for the study of Ca2+ voltage-gated channels, or spider/snake toxins for other ion channel classes. To
identify novel SOCE effectors, we analyzed the effects of 2-aminoethyl diphenylborinate (2-APB) and its analogues.
2-APB is a molecule known to both potentiate and inhibit T cell SOCE, but it is also an effector of TRP channels
and endoplasmic reticulum Ca2+-ATPase.
Results: A structure-function analysis allowed to discover that the boron-oxygen core present in 2-APB and in the
borinate ester analogues is absolutely required for the dual effects on SOCE. Indeed, a 2-APB analogue where the
boron-oxygen core is replaced by a carbon-phosphorus core is devoid of potentiating capacity (while retaining
inhibition capacity), highlighting the key role of the boron-oxygen core present in borinate esters for the
potentiation function. However, dimesityl borinate ester, a 2-APB analogue with a terminal B-OH group showed an
efficient inhibitory ability, without any potentiating capacity. The removal or addition of phenyl groups respectively
decrease or increase the efficiency of the borinate esters to potentiate and inhibit the SOCE. mRNA expression
revealed that Jurkat T cells mainly expressed Orai1, and were the more sensitive to 2-APB modulation of SOCE.
Conclusions: This study allows the discovery of new boron-oxygen core containing compounds with the same
ability as 2-APB to both potentiate and inhibit the SOCE of different leukocyte cell lines. These compounds could
represent new tools to characterize the different types of SOCE and the first step in the development of new
immunomodulators.
Background
In lymphocytes, after T or B cell receptor cross-linking,
inositol 1,4,5-trisphosphate (IP3) is synthesized [1] and
induces Ca2+ ion release from the lumen of the endo-
plasmic reticulum (ER), allowing the opening of Ca2+
selective plasma membrane channels, known as store-
operated channels (SOC). The resulting increase of the
intracellular calcium concentration ([Ca2+]i) allows
activation of NFAT (Nuclear Factor of Activated T
cells) [2]. Inhibition of this Store-operated Calcium
Entry (SOCE) by SKF96365 impairs T lymphocyte acti-
vation and subsequently interleukin 2 synthesis [3].
Recent studies have described two proteins playing key
roles in SOCE: STIM1 and Orai1. STIM1, present in the
ER membrane, senses the luminal Ca2+ concentration,
and translocates near the plasma membrane during Ca2+
release, where it directly interacts with Orai1 protein
forming the channel pore [4-6]. The R91W mutation of
Orai1 renders the channel non-functional, and is respon-
sible of a severe immunodeficiency [4]. Two Orai1
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homologue genes have been described, Orai2 and Orai3.
When expressed in HEK293 cells (with STIM1), the
three Orai are able to produce or increase the SOCE [7].
However, despite their high homology, only Orai1 is able
to restore the SOCE of SCID T cells [4,8]. Furthermore,
Orai2 and Orai3 could show slight differences in kinetics
and pharmacology.
Due to the key role of Ca2+ influx in lymphocyte acti-
vation and proliferation, the use of effectors to modulate
the Orai1-containing channels has appeared as a new
and promising way to modulate lymphocyte activities
and could represent a new way for the treatment of
inflammatory diseases [9,10]. Although several pharma-
ceutical companies have developed molecules acting on
SOCE, no specific SOCE effectors have been character-
ized [11].
One of the most interesting and promising molecule is
a boron-containing molecule, 2-aminoethyl diphenylbor-
inate (2-APB). 2-APB was originally described as a
plasma membrane permeant inhibitor of IP3 receptors
in human platelets and neutrophils [12], however it also
impairs Sarcoplasmic-Endoplasmic Reticulum Ca2+
ATPase activity at high concentrations (Kd > 200 μM),
inducing a store Ca2+ leak [13-15] and directly blocks
SOCE in the same range of concentration as for IP3
receptor inhibition [16]. Furthermore, 2-APB has a dual
effect on Jurkat T cell SOCE: potentiation at low con-
centration (1-5 μM) and inhibition at > 50 μM [17].
Similar behaviour has been described on human T, rat
basophilic leukemic RBL-2H3 and chicken B DT40 cells
[4,17,18]. 2-APB is also able to activate members of the
TRP channel family at high concentrations (100 μM,
TRPV1, V2 and V3 [19,20]) and to inhibit some others
(TRPC3, C6 and C7 [21]). The effects of 2-APB on
SOCE has been extensively studied in T cells but data
on other cell types of hematopoietic origin is poorly
documented.
Recently, several works have been published on 2-APB
analogues. Thus, several analogues of 2-APB (1; Figure 1)
have been described and tested on platelets and CHO
cells, where 2-APB and analogues are only inhibitory
[22-24]. On these cells, the boron-oxygen core (BOC)
was shown not to be an absolute prerequisite for inhibi-
tion, but minor changes of the structure of 2-APB (such
as replacement of the boron by a carbon atom and the
terminal NH2 by a N(CH3)2 as in diphenhydramine)
result in the loss of SOCE inhibitory activity [23]. Diphe-
nylborinic anhydride (DPBA, 2; Figure 1) and 2,2-diphe-
nyltetrahydrofuran (DPTHF, 3; Figure 1), two analogues
lacking the aminoethyl group were still efficient showing
that the aminoethyl group plays no role in SOCE inhibi-
tion by 2-APB at least in platelets [23]. More recently,
Mikoshiba’s group realized the synthesis of 2-APB
dimers, some of which demonstrated a 20-45 fold
increase in inhibition capacity [25]. However, no struc-
ture-function studies have been performed on SOCE
potentiation ability of 2-APB analogues.
The aim of this study was to identify which part of the
2-APB molecule is required for potentiation (and inhibi-
tion) of SOCE by using analogues modified in the three
parts of the molecule: the BOC, the ethanolamine group
and the phenyl rings. We show that the BOC is an abso-
lute requirement for the potentiating ability of 2-APB
(but not for the inhibitory capacity), and that the num-
ber of phenyl rings is linked to the capacity of the mole-
cule to potentiate/inhibit. We also confirm that the
ethanolamine group is not required for potentiation and
inhibition of SOCE in other cells.
Results
Dual effects of borinate esters (2-APB, DPBA and 2-ABB)
on SOCE
To visualize the SOCE, we treated the cells with 1 μM
thapsigargin (TG) in a Ca2+-free medium during 10
min: this treatment allows the release of Ca2+ ions from
the ER (Figure 2A), and subsequently the opening of the
Store-Operated Channels (SOC). Addition of 1 mM
CaCl2 then induced an increase of the intracellular Ca
2+
concentration ([Ca2+]i) due to the entry of Ca
2+ ions
through SOC. As previously described in human Jurkat
T [17] and chicken DT40 B cells [18], 2-APB has dual
effects on human BL41 B cell SOCE: potentiation at 10 μM
(208 ± 8%), inhibition at 50 μM (Figure 2A and 2C). As [Ca2
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Figure 1 Structure of 2-APB and analogues. Three structures of
2-APB are depicted besides analogues: open-chain monomer, ring
monomer when a ring is created by an N ® B coordinate bond,
dimeric form, when N ® B bonds are created between two
molecules of 2-APB.
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Figure 2 Borinate esters have dual effects on store-operated calcium entry. A. Cytosolic calcium concentration measurement of BL41 cells
using indo-1 fluorescence. Cells were treated 10 min with TG 1 μM to allow Ca2+ release from ER and opening of SOC channels. After 10 min, 1
mM CaCl2 was re-added, allowing Ca
2+ entry through SOC channels. Different 2-APB concentrations were applied 30 s prior to CaCl2. Error bars
were omitted for clarity (maximum ~ ± 70 nM). B. Mn2+ quenching of indo-1 in BL41 cells stimulated by potentiating and inhibitory
concentrations of 2-APB. Cells were pre-treated 10 min with TG 1 μM allowing Ca2+ release from ER and opening of SOC channels. 60 s after
beginning of the recordings, 100 μM MnCl2 was added. At 120 s, potentiating concentration of 2-APB (10 μM) was added, followed 60 s later by
inhibiting concentration of 50 μM. Fluorescence of indo-1 was recorded at 430 nm. Results expressed relative fluorescence prior to MnCl2
adding. C. 2-APB, DPBA and 2-ABB concentrations differently regulate SOCE of BL-41 cells. Experiments were done as in figure 1A, and peak [Ca2
+]i was expressed as % of peak [Ca
2+]i recorded in absence of any borinate ester compounds. Borinate ester compounds were added 30 s prior
to CaCl2. D. Mn
2+ quenching of indo-1 in BL41 cells stimulated by potentiating and inhibitory concentrations of DPBA. Same as in figure 2B,
except that 3 and 50 μM DPBA were used. E. Mn2+ quenching of indo-1 in BL41 cells stimulated by potentiating and inhibitory concentrations
of 2-ABB. Same as in figure 2B, except that 30 and 100 μM 2-ABB were used. F. Values of Indo-1 quenching in presence of the borinate esters
were normalised to values obtained in the lonely presence of Mn2+ ions.
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+]i is the result of an equilibrium between Ca
2+ ion influx
and Ca2+ efflux, we calculated a Ca2+ ion influx rate when
the Ca2+ efflux is greatly reduced [26]. During the first
10-20 s after CaCl2 adding, [Ca
2+]i is still low and the Ca
2+
pump activity to extrude Ca2+ from the cell is greatly
reduced, meaning variations of [Ca2+]i are due to Ca
2+ ion
influx. The rate was twofold increased in the presence of
10 μM 2-APB (32.4 ± 7.8 nM/s vs. 62.5 ± 11.5 nM/s). In the
presence of 50 μM 2-APB, the Ca2+ influx rate was largely
decreased (< 1 nM/s) and the [Ca2+]i increase after CaCl2
adding was largely blunted (Figure 2A).
These results were confirmed by indo-1 quenching
experiments with Mn2+ ions: as Mn2+ ions enter the
cells by the same channels as Ca2+ ions, they can not be
pumped back to the external medium by the plasma
membrane Ca2+ ATPases (PMCA) and lead to indo-1
fluorescence quenching at 430 nm [27]. After 10 min
treatment by TG to open SOC, addition of 100 μM
MnCl2 led to a rapid decrease of 430 nm fluorescence
(Figure 2B). The quenching was twofold increased in
the presence of 10 μM 2-APB (decrease of indo-1 430
nm fluorescence by -0.39 ± 0.03%/s vs. -0.22 ± 0.01%/s),
but decreased with 50 μM 2-APB (-0.06 ± 0.01%/s vs.
-0.22 ± 0.01%/s, Figure 2B). In BL41 cells and the
absence of TG, CaCl2 addition induced a slight increase
of [Ca2+]i (not shown). Thus, these experiments show
for the first time that 2-APB directly acts on Ca2+ ion
entry through SOC in the human B cell line BL41, with
dual effects, potentiation at low, inhibition at higher
concentrations.
Diphenylborinic anhydride (DPBA) and 2-aminoethyl
dibutylborinate (2-ABB, 4; Figure 1) have also dual
effects on BL41 cell SOCE (Figure 2C). DPBA, a 2-APB
analogue with two pairs of diphenylborinate, has
recently been shown to inhibit platelet SOCE [23]. In
BL41 cells, when DPBA was added, maximal potentia-
tion of SOCE was observed at 3 μM, whereas inhibition
was at concentrations higher than 10 μM (Figure 2C).
Furthermore, DPBA appeared to potentiate SOCE activ-
ity with a slightly greater efficacy than 2-APB (255 vs.
208%). Thus, BL41 cell SOCE was three times more sen-
sitive to the enhancing and inhibitory effects of DPBA
than with 2-APB (Figure 2C). These results were con-
firmed by indo-1 quenching experiments (Figure 2D):
Mn2+ quenching was twofold accelerated with 3 μM
DPBA (-0.35 ± 0.02%/s vs. -0.17 ± 0.01%/s) and slowed
by 50 μM (-0.06 ± 0.02%/s vs. -0.17 ± 0.01%/s).
2-ABB, another 2-APB analogue where the two phenyl
rings are replaced by two butyl groups, was further shown
to have a dual effect on BL41 cell SOCE (Figure 2C), with
a maximum of potentiation at 30 μM (201 ± 9%), and
inhibition at > 50 μM. Potentiation capability was in the
same order of magnitude than 2-APB’s (201 vs. 208%),
but slightly weaker than DPBA’s (201 vs. 255%). BL41
SOCE sensitivity to 2-ABB is weaker than for DPBA and
2-APB (Figure 2C). Indo-1 quenching by Mn2+ ions
confirmed this result: 30 μM 2-ABB accelerated the
quenching (-0.32 ± 0.02%/s vs. -0.12 ± 0.01%/s), when 100
μM slowed it (Figure 2E, -0.07 ± 0.02%/s vs. -0.12 ±
0.01%/s).
Differential effects of dimesitylborinic acid (DMBA) and
phenylboronic acid (PBA) on SOCE
As diphenylborinic acid is unstable, we chose dimesityl-
borinic acid (DMBA, 5; Figure 1) which is commercially
available and stable. This compound is a 2-APB mole-
cule without an ethanolamine group (and subsequently
with a terminal B-OH), and where the two phenyl rings
are replaced by two mesityl groups. DMBA was not able
to potentiate SOCE at 2-APB potentiating concentra-
tions, but clearly showed an efficient inhibitory capacity
(Ki ≈ 4 μM, Figure 3A). Indeed, DMBA was close to the
efficiency obtained with SKF96365, another common
SOCE inhibitor (Ki ≈ 3.3 μM, not shown). The inhibi-
tory capacity was confirm by Mn2+ quenching of indo-1:
1 μM DMBA (-0.13 ± 0.01%/s vs. -0.17 ± 0.01%/s),
20 μM. (-0.08 ± 0.01%/s vs. -0.17 ± 0.01%/s, Figure 3B).
As 2-APB and DMBA act in the same range of concen-
trations, we performed competition experiments. Used
at 10 μM, 2-APB was potentiating, DMBA inhibiting
(Figure 3C, D). However, when DMBA was added 100 s
after CaCl2, in the presence of 2-APB (Figure 3C), there
was a clear and fast decrease of [Ca2+]i to values
obtained when DMBA is used alone (Figure 3D). Inver-
sely, when 2-APB was added 100 s after CaCl2 adding in
presence of DMBA (Figure 3D), there was no increase
of [Ca2+]i. Thus, DMBA could impair 2-APB-induced
potentiation of SOCE, whereas 2-APB could not avoid
DMBA-induced inhibition of SOCE. This shows that
DMBA inhibits the SOCE and can bypass the 2-APB-
dependent potentiation.
Last we tested phenylboronic acid (PBA, 6; Figure 1),
which can be considered as a hemi-diphenylborinic acid.
PBA was devoid of either potentiating or inhibitory
activity on SOCE (Figure 3E), suggesting that the two
phenyl or mesityl rings must be on the same boron
atom to give activity to the 2-APB analogue.
2-APB analogues without the B-O core are not able to
potentiate SOCE
Thus, compounds containing a terminal B-OH (DMBA
and PBA) do not appear to behave like compounds
containing a central B-O ("BOC”, 2-APB, DPBA and
2-ABB), suggesting a requirement of the BOC for the
potentiating activity of 2-APB analogues. To confirm
this hypothesis, we performed experiments with 2-APB
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Figure 3 Non-borinate esters are either uneffective or inhibitors of SOCE. Dose-response curve of [Ca2+]i to 2-APB analogues were
obtained as in figure 2C. A. DMBA, DPTHF and DP3A are inhibitors of SOCE. B. Mn2+ quenching of indo-1 in BL41 cells stimulated by two
concentrations of DMBA or 2-APB. Same as in figure 2B, except that 1 and 20 μM DPBA or 2-APB were used. C and D. Cytosolic calcium
concentration measurement of BL41 cells in 2-APB/DMBA competition experiments. Cells were treated 400s with TG 1 μM to allow Ca2+ release
from ER and opening of SOC channels. Then 1 mM CaCl2 was added, allowing Ca
2+ entry through SOC channels. 2-APB 10 μM ("2-APB”, C),
DMBA 10 μM ("DMBA”, D) or 2-APB 10 μM + DMBA 10 μM ("2-APB + DMBA”, C and D) were applied 30 s prior to CaCl2. In competition
experiments, DMBA 10 μM was applied 100 s after CaCl2 adding on cells treated by 2-APB ("2-APB then DMBA”, C) or 2-APB 10 μM was applied
100 s after CaCl2 adding on cells treated by DMBA ("DMBA then 2-APB”, D). Error bars were omitted for clarity (maximum ~ ± 50 nM). E.
Diphenhydramine and phenytoine are weak inhibitors of SOCE, although PBA is inefficient. Same experiment as done in figure 3A. F. Mn2+
quenching of indo-1 in BL41 cells by low and high concentrations of DPTHF and DP3A, compared to 2-APB. Same protocol was used as in
figure 2B. The two analogues were used at 10 μM and 50 μM. G and H. Values of Indo-1 quenching in presence of the borinate esters were
normalised to values obtained in the lonely presence of Mn2+ ions, respectively from B and F.
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analogues devoid of B-O. Several of these analogues
(Phenytoin, diphenhydramine, DPTHF) have been tested
on platelet SOCE and described as inhibitors [23]. It has
been hypothesized that the terminal amine and the
boron of 2-APB could form an internal coordinate-
bound, resulting in the formation of a ring ("close” or
“ring”, [23]).
Diphenhydramine (7; Figure 1), an analogue without
boron and where the terminal amine bears two methyl
groups cannot form the internal coordinate (analogue of
the “open” form of 2-APB). Phenytoine (8; Figure 1) is an
analogue with a third ring containing two ketone groups
and two nitrogen atoms (analogue of the “ring” form of
2-APB). Diphenhydramine and phenytoin were weak
inhibitors of BL-41 SOCE (with a maximum of ~35% at
300 μM), and totally devoid of potentiation ability, as
previously described on platelets ([23], Figure 3E).
2,2-diphenyltetrahydrofuran (DPTHF (3; Figure 1)), an
analogue of the 2-APB ring form with a more neutral
third ring, was a more effective inhibitor with a Ki ~
50 μM, but was totally devoid of potentiating ability
(Figure 3A), as in platelets [23]. At 10 μM, DPTHF was
a slight inhibitor (-0.11 ± 0.00%/s vs. -0.16 ± 0.01%/s),
more efficient at 50 μM (-0.06 ± 0.00%/s vs. -0.16 ±
0.01%/s) when used in Mn2+ quenching experiments of
indo-1 (Figure 3F).
3-(diphenylphosphino)-1-propylamine (DP3A (9;
Figure 1)) is a 2-APB analogue where the BOC is replaced
by a carbon-phosphorus core. This little change resulted
in drastic consequences: DP3A was only inhibitory, with a
Ki similar to DPTHF’s (Figure 3A). In indo-1 quenching
experiments by Mn2+ ions, DP3A was a weak inhibitor
at 10 (-0.11 ± 0.02%/s vs. -0.18 ± 0.03%/s) and 50 μM
(-0.05 ± 0.02%/s vs. -0.18 ± 0.03%/s), confirming its total
absence of potentiating effect on the divalent ion influx
(Figure 3F). Although DPTHF and DP3A were only inhibi-
tory, they were also less efficient, as higher concentrations
were needed to get the same inhibition as done by 2-APB
(Figure 3A). This also confirms that the BOC is not an
absolute requirement to confer the inhibitory ability of the
compound.
Dual effects of borinate esters (2-APB, DPBA and 2-ABB)
are observed in other leukemia/lymphoma cell lines
As the most extensively studied SOCE is CRAC of T lym-
phocytes [17] we tested whether the identified structure
effects of 2-APB analogues were also relevant to T cells
and other cell lines. As previously shown, 2-APB has dual
effect on Jurkat cell SOCE, potentiation at 3 μM and
inhibition at > 20 μM 2-APB (Figure 4A). SOCE of
monocytic U937 cells was potentiated and inhibited by 2-
APB in a similar way to BL-41 SOCE: potentiation at
10 μM, inhibition at > 50 μM (Figure 4A). Thus, the
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Figure 4 Borinate esters have dual effects on SOCE of myeloid
and lymphoid hematopoietic cells. Dose response curves for 2-
APB (A), DPBA (B) and 2-ABB (C) obtained on SOCE of BL-41, U937
and Jurkat cells. Same protocol was used as in figure 2A to
generate the dose-response curve of [Ca2+]i increase after Ca
2+ re-
adding to borinate compound concentrations. Values are expressed
as % of the peak [Ca2+]i increase measured in absence of any
effector.
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2-APB dose-response curve obtained on Jurkat cell SOCE
showed a leftward shift, indicating a near three-fold
higher sensitivity to 2-APB than B lymphocyte BL41’s
and monocytic U937’s. Dose-response curves obtained
with BL30 (Burkitt lymphoma B cell line), THP1 (mono-
blastic cell line) and NB4 cells (promyelocytic cell line)
were similar to BL41’s and U937’s (not shown). These
results indicate that the previously reported effects of
2-APB on human T cell SOCE [17] can also be observed
in other cell types of hematopoietic origin.
DPBA was also 3 fold more efficient than 2-APB in
Jurkat and U937 cells (Figure 4B). Remarkably, Jurkat
cells remained three times more sensitive to DPBA than
the other cell lines, as with 2-APB (Figure 4B).
2-ABB had the same dual effect on U937 and Jurkat
cell SOCE (Figure 4C). As with BL41 cells, U937 and
Jurkat cells were 2-3 fold less sensitive to 2-ABB than to
2-APB (Figure 4C). Like with 2-APB and DPBA, Jurkat
cell SOCE was three-fold more sensitive to the 2-ABB
than BL41 and U937 SOCE. Thus, Jurkat cell SOCE is
2-3 fold more sensitive to borinic ester potentiation and
inhibition than other cell SOCE.
Orai isoform expression
SOCE is directly dependent on Orai protein expression.
Three Orai isoforms have been characterized in human
cells and exhibit different sensitivities to 2-APB when
over-expressed in HEK 293 cells [28]. We studied Orai
isoform expression in our cell lines by using qRT-PCR. As
shown in Figure 5, the three cell lines expressed different
amounts and ratio of the three isoforms. Thus, although
Orai1 is the main isoform in Jurkat T cells at the mRNA
scale (with low amount of Orai2 and 3), Orai2 is the main
isoform in BL41 B cells and U937 monocytic cells express
mainly Orai3, with a slightly weaker amount of Orai2.
Noteworthy, BL41 B cells do not express Orai3. Thus, the
difference of Orai expression could be responsible of the
sensitivity difference to 2-APB/borinate ester dual effects
in our cell lines. Even if the Orai1 mRNA is not the main
Orais mRNA, the SOCE is almost abolished at [2-APB] >
50 μM in the three cell lines, meaning Orai1 proteins form
the main channel.
Borinate esters are also Ca2+ release inhibitors
To test the SOCE-specificity of the 2-APB analogues, we
performed the same kind of experiment, except that the
cells were stimulated with an anti-IgM antibody instead
TG. In these conditions, anti-IgM antibodies induce
synthesis of IP3 and Ca
2+ ion release through IP3 recep-
tor of the ER [29]. At their maximal SOCE potentiation
concentration, the three borinate esters already impaired
the Ca2+ release by the ER (Figure 6A).
DMBA at 10 (not shown) and 20 μM was also able to
totally block the Ca2+ release by the ER, in a range of
concentration similar to concentration needed to block
the SOCE (Figure 6B). In contrast, at a concentration
with almost no effect on SOCE (Figure 3A), 10 μM
DP3A tightly blocked the Ca2+ release (Figure 6B).
BL-41 U937 Jurkat
0.0
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Orai1
Orai2
Orai3
A
U
Figure 5 Orai isoform mRNA are differently expressed in
hematopoietic cells. qRT-PCR results were expressed as arbitrary
units with expression of Orai3 in Jurkat equal 1. See material and
methods for details.
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Figure 6 2-APB and analogues are Ca2+ release inhibitors. BL-41
cell cytosolic concentrations were measured as in figure 1. To
induce Ca2+ release by the ER, cells were treated with 0.5 μg/ml
anti-IgM antibody at t = 30 s. According to the treatment, cells
were pre-treated with 2-APB or analogues during 5 min prior anti-
IgM antibody stimulation. Error bars were omitted for clarity but
were < 4 nM.
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Discussion
In this work, we clearly show that 2-APB is able to exert
dual effects (potentiation and inhibition) on the Ca2+
influx of various cell lines of hematopoietic origin, and
may be considered as the parent of a new family of
molecules with this dual efficacy. We were able to define
which part of the 2-APB molecule is required for poten-
tiation and/or inhibition of the Ca2+ influx through
store-operated channels. Despite the same kind of activity
in hematopoietic cell lines, a slight difference in sensitivity
to 2-APB and its analogues can be observed, and could be
due to the relative expression of the three Orai proteins.
Though 2-APB is a small molecule, three parts can be
distinguished: an ethanolamine chain, a boron-oxygen
core (BOC) and two phenyl rings. The presence of a
boron atom with an amine chain allows the formation
of an internal coordinate, but the boron atom is also
able to interact with N and O atoms of amino-acids, as
shown in the case of bortezomib binding to proteasome
[30]. The use of analogues helped to understand which
part of the 2-APB is important to inhibit SOCE of plate-
lets [22,23], but nothing was known about the potentia-
tion process, as platelet SOCE is clearly not potentiated
by 2-APB and analogues.
DPBA had been previously used and was known as a
five fold more potent inhibitor of platelet SOCE than 2-
APB (2 μM vs. 10 μM, [23]), meaning the ethanolamine
group plays no role in SOCE inhibition (and the N-B
internal coordinate bond as well). DPBA could also acti-
vate some TRP channels at concentrations > 100 μM
[31,32]. In our experiments, DPBA is ~3 fold more effi-
cient than 2-APB, and is able to potentiate the Ca2+
influx. Thus, [Ca2+]i variations are increased by 200-
250% at 3-10 μM, concentrations without any known
effect on TRP channels. As DPBA does not possess an
ethanolamine group, this confirms that this group plays
no role in potentiation process.
2-ABB, a compound never used in Ca2+ signalling, is
an analogue of 2-APB where the two phenyl groups
were replaced by two butyl. On the three cell lines, we
found that 2-ABB, like 2-APB and DPBA, has dual effect
on Ca2+ influx, meaning that the two phenyl rings are
not an absolute requirement for potentiation and inhibi-
tion processes. However, 2-ABB is less potent to
potentiate AND inhibit SOCE than 2-APB and DPBA. A
clear correlation seems to exist between the number of
phenyl rings in the molecule and its ability to potenti-
ate/inhibit SOCE: DPBA (4 phenyl groups) > 2-APB (2)
> 2-ABB (0). Thus, it seems that the phenyl rings do
not play a direct role in potentiation, but rather favour
it. We can assess that after the binding of 2-APB to
the channel protein by the BOC, the two phenyl rings
strengthen the binding by a second interaction. In
DPBA, the presence of four phenyl rings reinforces this
binding. It was previously shown that addition of a phe-
nyl ring to the 2-APB molecule could increase its inhibi-
tory efficacy on platelet SOCE [22]. Dimers of 2-APB
(with four phenyl rings) had been recently shown to
have higher ability to inhibit SOCE than 2-APB [25].
It is also remarkable that the ratio between the con-
centrations of compound to have maximal potentiation,
and to have inhibition is similar with the three borinate
esters (from BL41 cells, but same kind from Jurkat and
U937 cells): 2-APB 10 μM/100 μM, DPBA 3 μM/30 μM,
2-ABB 30 μM/200 μM (this last value was extrapolated
from graphs): this clearly shows that potentiation and
inhibition are linked. Interestingly, 2-ABB is the first
described SOCE inhibiting molecule without any struc-
tural rings.
Sensitivity to potentiation/inhibition by borinate esters
varies among cell line SOCE: thus, these compounds are
three fold more potent on Jurkat cell SOCE. Using qRT-
PCR, we showed the the cell lines used in this study do
not express the same Orai proteins, and in different
ratios (Figure 5). Thus we confirmed that the main Orai
protein expressed by Jurkat T cells is Orai1 [4], although
BL41 cells express mainly Orai2, and U937, a mix of
Orai2 and Orai3 (Figure 5). Of note, in B cells from
patient with a non-functional Orai1 inducing a SCID,
SOCE is not abrogated as in T cells, but decreased,
allowing a partial NF-AT activation [4,33]. This could
be due to the fact that B cells express significantly more
Orai2 than Orai1 proteins, and Orai2 proteins could
play a role in B cell SOCE. However the role of Orai2
(and Orai3) in SOCE is controversial: although Orai2
(and Orai3) could form SOCE when over-expressed
with STIM1 in HEK293 cells [28], heterologous expres-
sion of Orai2 in SCID T cells cannot restore SOCE [8].
While Orai1 has been clearly shown to encode the SOC
pore in many cells, a recent work showed that Orai3 is
the SOC pore of estrogen receptor positive breast can-
cer cell lines, in contrast to estrogen receptor negative
cell line which use Orai1 [34]. The role of transient
receptor potential canonical protein (TRPC) in forming
store operated channels with Orai1 protein is also con-
troversial: some authors show a clear association [35,36],
when others found none [37]. As 2-APB is a known
inhibitor of TRPC1, 3 and 6 channels [21], we cannot
rule out that in B cells, TRPC proteins form the store-
operated channel pore in association with Orai1, and
play a role in the SOC pharmacology.
Since the molecular characterization of Orai1 [4], Orai
proteins have been fully studied in heterologous expres-
sion system [8,28]. Although these systems allow easier
characterization, due to larger currents, they should
be used with care. Thus, in one of the first studies
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reconstituting SOCE with Orai1 and STIM1 over-
expression in HEK293 cells, it was shown that 2-APB
was able to inhibit SOCE but not to enhance it (Figure
1C, [38]). Thus, in over-expressing system with large
amount of Orai1 and STIM1 proteins, inducing large
increase of [Ca2+]i (3500 nM), 2-APB is not potentiating.
Furthermore, the expression levels of Orai1 and STIM1
have been shown to affect the Ca2+ conductance and
the potentiation of the currents by 2-APB [39]. The use
of recombinant Orai/STIM seems to be accurate for the
study of drugs with inhibition ability, but not for drugs
with potentiating ability. Furthermore, SOCE is a large
family, with different kinetics and pharmacological prop-
erties, and the expression of Orai1 and STIM1 can not
reconstitute the different types of SOCE, because all the
partners forming a SOC are not known yet (TRPC pro-
teins ? other ?). The use of cell lines to study the phar-
macology is complementary to the use of recombinant
system, but crucial to identify new compounds with
potentiating ability.
The presence of a boron-oxygen link in a molecule
does not mean that a compound has potentiating ability
on SOCE. DMBA, which resembles 2-APB without the
ethanolamine group but a terminal hydroxyl group
bound to the boron atom, has shown great capacity to
block SOCE, without any potentiating effect. The dipep-
tidyl boronate pyrazylcarbonyl-Phe-Leu-boronate, also
known as PS-341 or bortezomib (commercial name:
Velcade®) is a well known inhibitor of proteasome used
in the treatment of multiple myeloma. Its pharmaco-
phore is a terminal boron atom with two hydroxyl
groups [40,41]. Bortezomib blocks protein degradation
by binding to the terminal threonine of 20S core particle
with a Ki < 1 nM [40,42]. Remarkably, the same mole-
cule without the boron atom ("aldehyde form”) largely
loses its proteasome inhibitory capacity (Ki = 1.6 μM)
[42]. Boron atom presence is also an absolute require-
ment in serine protease inhibitors [43]. Thus, the same
kind of relationship seems to exist between SOC pro-
tein/2-APB and proteasome/bortezomib.
The absolute requirement of the boron atom for poten-
tiation was confirmed by DP3A. Despite its closely
related structure to 2-APB’, DP3A had never been used
in Ca2+ signalling before this work. Remarkably, this
compound where a P-C core replaces the BOC present in
2-APB, has lost its ability to potentiate SOCE of hemato-
poietic cell lines (Figure 3A and 3D). This result clearly
highlights the key role of the BOC in the potentiation
ability of 2-APB. However, DP3A is still inhibitory even if
higher concentrations are needed to inhibit SOCE than
2-APB. Thus, replacement of the BOC in the 2-APB
molecule impairs the ability of the molecule to potentiate
SOCE and decrease its capability to inhibit it. It also con-
firms that the BOC is not required for a molecule to be
inhibitory, as shown previously with DPTHF [23] and in
the present work (Figure 3A and 3D).
The dual effect of borinate esters on SOCE is complex
to analyse because the binding sites of 2-APB are not
clearly established yet. Thus, before the discovery of
Orai1, the study of the T cell SOCE, characterized the
dual effect of 2-APB and the authors hypothesize the
existence of two binding sites, one potentiating with
high affinity, the other one with lower affinity and inhi-
bitory [17]. The inhibitory target of 2-APB seems to be
STIM1 itself [44], but 2-APB can also bind to the selec-
tivity filter of the Orai protein, widening the size of the
pore, resulting in potentiation of the current [45]. How-
ever, the same authors provide an alternative explana-
tion where 2-APB interacts with the CRAC channels to
widen the channel pore, and when more 2-APB interact
with the channel, a change of channel conformation
may prevent ions to pass through it. Furthermore, SOC
are made with four Orai proteins, meaning a SOC has
potentially four 2-APB binding sites, and nothing is
known yet about how many 2-APB molecules are
required to widen the pore or to block it. Our work
could provide new tools to study 2-APB binding sites.
Thus, DMBA is a compound able to counteract the
potentiating effect of 2-APB. Our preliminary results
with DMBA/2-APB competition could not explore the
binding sites of the molecules, but we could make two
main hypothesis: (i) DMBA and 2-APB have the same
binding site. As DMBA impaired 2-APB potentiating
effect, and 2-APB can not remove the DMBA inhibition,
we could think that DMBA has a higher affinity for the
binding site than 2-APB. (ii) DMBA and 2-APB have
two different binding sites and binding to the inhibitory
binding site (STIM1 ?) bypasses the potentiation binding
site. Interesting is the case of Orai3: Orai3 channels do
not need stimulation by STIM1 to be opened, and 2-
APB has only potentiating ability. If DMBA binds to
STIM1, it should have no effect on Orai3 currents.
Recently, it has been discovered for the first time that a
physiological SOCE could be mediated by Orai3 pro-
teins (usually Orai1’ are, [34]). It will be therefore inter-
esting to test the effect of DMBA on these breast cancer
cells.
However, all the compounds used in this study are not
SOCE specific, as they also exert ability to inhibit the
Ca2+ release by the ER. Thus, when borinate esters are
at their maximal potentiating concentration, they are
already at a concentration fully inhibiting the Ca2+
release (Figure 6), impairing their future use as specific
immune-modulator.
Conclusion
The results from the present study clearly highlight the
role of the Boron-Oxygen core in the ability of borinate
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ester molecules to potentiate Ca2+ entry in hematopoie-
tic cells. The design of potentiating compounds requires
the absolute presence of a BOC, whereas design of inhi-
bitors does not. Strikingly, terminal B-OH could give
high inhibitory ability to molecules (DMBA). This work
could represent the first step for the development of
new molecules with immunomodulatory properties:
thus, a potentiating compound could be useful to
enhance responses of blood cells from immunodeficient
patients, or to increase Ca2+ toxicity in leukemia cells.
Methods
Cell lines
The BL30 and BL41 (Burkitt B lymphomas), Jurkat
(acute T cell leukemia), U937 and THP1 (monocytic cell
lines) and NB4 (promyeloid leukaemia cell line) cell
lines were maintained in RPMI-1640 medium (Lonza,
Verviers, Belgium) supplemented with 10% fetal calf
serum and 2 mM ultraglutamine (Invitrogen, Cergy-
pontoise, France), at 37°C in a 5% CO2 humidified
atmosphere. All cell lines used were from ATCC-LGC
Promochem (Molsheim, France) except BL-30 and BL-
41 cells which were a gift of Irene Joab [46].
Measurement of intracellular Ca2+ concentration ([Ca2+]i)
The intracellular Ca2+ concentration was recorded by a
fluorimetric ratio technique. Cells were centrifugated
and resuspended in Phosphate Buffer Saline medium
(PBS, Cambrex, Belgium) supplemented with 1 mg/ml
Bovine Serum Albumine (Sigma, Saint Quentin Fallavier,
France) under gentle agitation. The fluorescent indicator
indo-1 was loaded by incubating the cells at room tem-
perature for 1 h with 4 μM indo-1-AM (Invitrogen/
Molecular Probes, Eugene, USA). Cells were then
spinned and resuspended in Hepes Buffer Saline (HBS)
medium without CaCl2 (in mM): 135 NaCl, 5.9 KCl, 1.2
MgCl2, Hepes 11.6, glucose 11.5, pH 7.3 adjusted with
NaOH.
One million cells were put in a 1 cm width - 3 ml
quartz cuvette, and inserted in a spectrofluorophot-
ometer (RF-1501 Shimadzu Corporation, Japan),
equipped with a thermostatted (37°C) cuvette holder.
Ultraviolet light of 360 nm was used for excitation of
indo-1, and emission at 405 and 480 nm were recorded.
Background and autofluorescence of the cells were
removed from the values measured at 405 and 480 nm.
The maximum indo-1 fluorescence (Rmax) was obtained
by adding 1 μM ionomycin to the bath in the presence
of 10 mM CaCl2. Minimum fluorescence (Rmin) was
determined following depletion of external Ca2+ by 5
mM EGTA. All the measures were sent to a PC compu-
ter and analyzed. [Ca2+]i was calculated according to the
equation [Ca2+]i = Kd (R-Rmin)/(Rmax-R), where Kd is
the apparent dissociation constant of indo-1 for Ca2+
(250 nM, [47]), and R is the ratio of fluorescence value
at 405 nM on the one at 480 nm [47].
To induce SOCE, the cells were treated for 10 min
with 1 μM TG in the absence of external Ca2+. After 10
min, 1 mM CaCl2 was added. For dose-response curves,
the peak [Ca2+]i was measured and expressed as a per-
centage of peak [Ca2+]i measured in absence of the test
compound. These experiments were done at least three
times, but for clarity, the SEM was not shown on traces,
but is less than 1-2% of the mean.
To calculate the Ca2+ influx rate (∆[Ca2+]i), we mea-
sure the variation of [Ca2+]i per second during the first
20 s after CaCl2 addition: in these conditions, the activ-
ities of the plasma membrane Ca2+ ATPases (PMCA)
and of the Na+/Ca2+ exchanger are largely reduced (and
the activity of SERCA is already inhibited by TG). Thus,
the ∆[Ca2+]i is only due to the Ca
2+ ion entry [26].
Mn2+ ion binding to indo-1 forms a non-fluorescent
complex. Thus, Mn2+ entry can be estimated by the
Indo-1 fluorescence quenching rate [48]. In these
experiments, SOCE was activated during 10 min with 1
μM TG without external Ca2+. Fluorescence of Indo-1
was recorded at 430 nm emission wavelength (excitation
wavelength 360 nm). We recorded this fluorescence
during 2-3 min, and only cuvettes with a stable value
were then used for the quenching experiment. At t = 60
s, 100 μM MnCl2 was added, and the Indo-1 fluores-
cence quenching was measured, and served as a control
value. According to the different experiments, 2-APB or
2-APB analogues were added at various concentrations,
and the quenching rates were normalised to the value
obtained in presence of only Mn2+ ions. These experi-
ments were done at least three times, but for clarity, the
SEM was not shown on traces, but is less than 1-2% of
the mean.
To test the effects of 2-APB and its analogues on the
Ca2+ release by the ER, the BL41 cells were stimulated
by an anti-IgM antibody (ABCam, Paris, France) instead
by TG, still in absence of extracellular Ca2+. This kind
of antibody cross-links to the B cell receptor induces
the synthesis of IP3 and Ca
2+ release through IP3 recep-
tors [29]. Cells were pretreated 5 min with 2-APB or an
analogue, then stimulated by 0.5 μg/ml anti-IgM anti-
body. These experiments were done at least three times,
but for clarity, the SEM was not shown on traces, but is
less than 1-2% of the mean.
Orai isoform expression
Total RNA was isolated from cell lines by using the
TRIzol® Reagent (Invitrogen) following the manufac-
turers’ instructions. RNA was quantified with Thermo
Scientific NanoDrop™ Spectrophotometers. Reverse
transcription was performed on 1 μg of total RNA.
After 3 min at 95°C, RNA was incubated for 1 h at 42°C
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with 50 units of M-MLV reverse transcriptase (Applied
Biosystems), 20 units of RNase inhibitor (Applied Bio-
systems), 2.5 mM random hexamers and dNTP at
1 mM in a final volume of 20 μl. Finally, reverse tran-
scriptase was denatured by heating for 5 min at 95°C.
We quantified transcripts of the GAPDH gene as the
endogenous RNA control. Each sample was normalized
on the basis of its GAPDH content, and results expressed
as N-fold differences in target gene expression relative to
the GAPDH gene (termed Ntarget), were determined
with the following formula: Ntarget = 2(∆Ct sample -
∆Ct calibrator), where the ∆Ct value of the sample was
determined by subtracting the average Ct value of the
target gene from the average Ct value of the GAPDH
gene. The Ntarget values of the samples were subse-
quently normalized such that the mean ratio of the sam-
ples with the lowest expression level would have a value
of 1. The nucleotide sequences of the primers used for
PCR amplification were as follows:
GAPDH-Forward:
GGACCTGACCTGCCGTCTAGAA
GAPDH-Reverse: GGTGTCGCTGTTGAAGTCAGAG
ORAI1-Forward: TCGGTCAAGGAGTCCCCCCAT
ORAI1-Reverse: GTCCTGTAAGCGGGCAAACTC
ORAI2-Forward: GCTGAGCTTAACGTGCCTATC
ORAI2-Reverse: GGAGTTCAGGTTGTGGATGTT
ORAI3-Forward: CCCTTAGTCCAGCTTCCAATC
ORAI3-Reverse: CCAAGGAGCGGTAGAAATGCA
PCR was performed using an ABI Prism 7700
Sequence Detection system (Perkin-Elmer Applied Bio-
systems) and the SYBR® Green PCR Master Mix
(Applied Biosystems). The thermal cycling conditions
comprised an initial denaturation step at 95°C for
10 min and 40 cycles at 95°C for 15 s and 60°C for
1 min. Experiments were performed in duplicates for
each data point.
Chemicals
2-aminoethoxydiphenyl borate (2-APB), 2-aminoethoxydi-
butyl borate (2-ABB), diphenylboronic anhydride (DPBA),
2,2-diphenyltetrahydrofuran (DPTHF), phenylborinic acid
(PBA), 3-(diphenylphosphino)-1-propylamine (DP3A),
phenytoin, diphenhydramine, dimesitylborinic acid
(DMBA) and 2-aminoethyl dibutylborinate (2-ABB) were
from Sigma-Aldrich (Saint Quentin Fallavier, France),
thapsigargin was purchased from Calbiochem-Merck
(Nottingham, UK). The structure of 2-APB and analogues
is given in Figure 1.
Statistical analysis
Given values are representative of at least 3 independent
experiments ± SEM. When used, a t-test < 0.05 is con-
sidered as significant.
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